Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
VBI Vaccines Inc (via Public) / VBI Vaccines to Present at Upcoming Scientific Conferences (Form 8-K) publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Access to $100 million in DIP Financing to Support Operations Operations Will Continue Uninterrupted and in the Ordinary Course During Restructuring Vendors .
Marathon Signals for Taproot forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
News provided by
Share this article
Share this article
SAN DIEGO, May 26, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 15 U.S. sites as of May 14, 2021.
The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. Since January 2021, GCAR has accelerated the pace of clinical site activation with increased awareness in the medical community of Kintara s arm of